About ATP-dependent RNA helicase DDX39A
ATP-dependent RNA helicase DDX39A (DDX39A) is a protein
from Homo sapiens identified by UniProt accession
O00148, 427 residues long.
MolForge cross-references it against 0 known binders and
60 disease associations.
Target properties
| Protein name | ATP-dependent RNA helicase DDX39A |
| UniProt accession | O00148 |
| Gene | DDX39A |
| Organism | Homo sapiens |
| Length | 427 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (60)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.33
- reticulocyte measurement · score 0.30
- reticulocyte count · score 0.29
- mean corpuscular hemoglobin concentration · score 0.27
- mean corpuscular hemoglobin · score 0.25
- Immature Reticulocyte Fraction Measurement · score 0.22
- hematocrit · score 0.22
- neoplasm · score 0.08
- hepatocellular carcinoma · score 0.08
- melanoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O00148-F1 | alphafold | PREDICTED | 85.27 | — |
Amino-acid sequence (427 residues)
MAEQDVENDL LDYDEEEEPQ APQESTPAPP KKDIKGSYVS IHSSGFRDFL LKPELLRAIV DCGFEHPSEV QHECIPQAIL GMDVLCQAKS GMGKTAVFVL ATLQQIEPVN GQVTVLVMCH TRELAFQISK EYERFSKYMP SVKVSVFFGG LSIKKDEEVL KKNCPHVVVG TPGRILALVR NRSFSLKNVK HFVLDECDKM LEQLDMRRDV QEIFRLTPHE KQCMMFSATL SKDIRPVCRK FMQDPMEVFV DDETKLTLHG LQQYYVKLKD SEKNRKLFDL LDVLEFNQVI IFVKSVQRCM ALAQLLVEQN FPAIAIHRGM AQEERLSRYQ QFKDFQRRIL VATNLFGRGM DIERVNIVFN YDMPEDSDTY LHRVARAGRF GTKGLAITFV SDENDAKILN DVQDRFEVNV AELPEEIDIS TYIEQSR
Explore ATP-dependent RNA helicase DDX39A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets